MedPath

Efficacy of Topiramate in the treatment of Schizophrenia

Phase 3
Conditions
Schizophrenia.
Schizophrenia
Registration Number
IRCT201303287373N3
Lead Sponsor
Arak University Medical of Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

age range 15-50 ;diagnosis of schisophrenia according to DSM4-TR criteria and clinical interview by psychiatrist ; informed written consent letter; a score of at least 60 in PANSS
Exclusion criteria :pregnancy;lactation; substance abuse;severe physical disease;epilepsy;use of Antiepileptic drugs ;contraindication of Topiramate

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
PANSS. Timepoint: before intervention and every 4 weeks. Method of measurement: clinical examination.
Secondary Outcome Measures
NameTimeMethod
Extrapyramidal side effects. Timepoint: before intervention and every 4 weeks. Method of measurement: clinical examination.
© Copyright 2025. All Rights Reserved by MedPath